Eric Zhang - 24 Oct 2022 Form 4 Insider Report for Aravive, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 24 Oct 2022
Net transaction value: +$500,000
SEC form: 4
Accepted by SEC: 26 Oct 2022, 17:02:12 UTC
Prior SEC filing: 26 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Abel Svitavsky, Attorney-in-fact

Key filing fact

Eric Zhang filed Form 4 for Aravive, Inc. on 26 Oct 2022.

Key facts

This page summarizes Eric Zhang's Form 4 filing for Aravive, Inc..
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 26 Oct 2022, 17:02.

Change

Previous filing in this sequence was filed on 26 Sep 2022.
Current net transaction value: +$500,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

This filing has been restated. Open the amended filing.

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARAV transaction

Common stock

Award

Transaction value: $500,000
Shares: +543,537
Change %: +63%
Price: $0.9199
Shares after: 1,403,303
Date: 24 Oct 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARAV transaction Derivative

Series A Warrants (right to buy)

Award

Transaction value
Shares: +271,769
Change %
Price
Shares after: 271,769
Date: 24 Oct 2022
Ownership: Direct
Underlying class: Common stock
Underlying amount: 271,769
Exercise price: $0.7949
Footnotes: F1, F2, F3

ARAV transaction Derivative

Series B Warrants (right to buy)

Award

Transaction value
Shares: +271,768
Change %
Price
Shares after: 271,768
Date: 24 Oct 2022
Ownership: Direct
Underlying class: Common stock
Underlying amount: 271,768
Exercise price: $0.7949
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

On October 24, 2022, Aravive, Inc. (the "Company") agreed to issue approximately $41.5 million of securities including shares of its common stock and warrants (the "Warrants") to purchase shares of common stock in a private placement transaction (the "Private Placement") to certain investors, including the reporting person. The combined purchase price of each share of common stock and accompanying Warrants is $0.9199.

Footnote F2

The Series A Warrants are exercisable at any time after the Authorized Share Increase (as defined below) and will expire on the date that is the later of (i) fifteen (15) months after the date of the Authorized Share Increase, or (ii) one (1) month after public announcement by or on behalf of the Company of the publication of top line data from the Company's Phase 3 trial of batiraxcept in platinum-resistant ovarian cancer.

Footnote F3

In connection with the Private Placement, the Company has agreed to convene a special meeting of its stockholders or to seek written consent of the stockholders no later than 120 days following the closing of the Private Placement to seek approval of an increase in the number of the Company's authorized shares of common stock pursuant to an amendment to the Company's Certificate of Incorporation (such increase, the "Authorized Share Increase") to allow for full sufficient authorized and unissued shares of common stock for the full exercise of all of the Warrants and the shares of common stock issuable upon exercise thereof.

Footnote F4

The Series B Warrants are exercisable at any time after the Authorized Share Increase and will expire thirty (30) months after the Authorized Share Increase.